Law360, New York (July 11, 2006, 12:00 AM EDT) -- With trials over the potential side effects of Merck & Co.’s former blockbuster Vioxx underway, the pharmaceutical giant may soon be headed to court on charges related to its second-biggest seller, Fosamax, in a slew of class action suits that allege the osteoporosis drug could lead to jaw deterioration.
Since April, plaintiffs firm Levin Papantonio Thomas Mitchell Echsner & Proctor PA has filed more than two dozen lawsuits in Florida federal court over the drug.
Timothy O’Brien, lead attorney in the Florida cases, told the L.A....
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.